Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons

被引:185
|
作者
Dong, Min [1 ,2 ]
Liu, Huisheng [1 ,2 ]
Tepp, William H. [3 ]
Johnson, Eric A. [3 ]
Janz, Roger [4 ,5 ]
Chapman, Edwin R. [1 ,2 ]
机构
[1] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA
[2] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA
[3] Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA
[4] Univ Texas Houston, Sch Med, WM Keck Ctr Learning & Memory, Houston, TX 77030 USA
[5] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E08-07-0765
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Botulinum neurotoxin E (BoNT/E) can cause paralysis in humans and animals by blocking neurotransmitter release from presynaptic nerve terminals. How this toxin targets and enters neurons is not known. Here we identified two isoforms of the synaptic vesicle protein SV2, SV2A and SV2B, as the protein receptors for BoNT/E. BoNT/E failed to enter neurons cultured from SV2A/B knockout mice; entry was restored by expressing SV2A or SV2B, but not SV2C. Mice lacking SV2B displayed reduced sensitivity to BoNT/E. The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. Finally, we demonstrate that BoNT/E failed to bind and enter ganglioside-deficient neurons; entry was rescued by loading exogenous gangliosides into neuronal membranes. Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons.
引用
收藏
页码:5226 / 5237
页数:12
相关论文
共 50 条
  • [31] Levetiracetam: the first SV2A ligand for the treatment of epilepsy
    Klitgaard, Henrik
    Verdru, Peter
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (11) : 1537 - 1545
  • [32] Structural insights into SV2A and the mechanism of racetam anticonvulsants
    Bradberry, Mazdak M.
    Chapman, Edwin R.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2024, 31 (12) : 1818 - 1820
  • [33] Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells
    Dong, M
    Richards, DA
    Goodnough, MC
    Tepp, WH
    Johnson, EA
    Chapman, ER
    JOURNAL OF CELL BIOLOGY, 2003, 162 (07): : 1293 - 1303
  • [34] Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons
    Dong, Min
    Tepp, William H.
    Liu, Huisheng
    Johnson, Eric A.
    Chapman, Edwin R.
    JOURNAL OF CELL BIOLOGY, 2007, 179 (07): : 1511 - 1522
  • [35] Imaging the Effect of Ketamine on Synaptic (SV2A) Density
    Holmes, Sophie
    Finnema, Sjoerd
    Naganawa, Mika
    DellaGioia, Nicole
    Holden, Daniel
    Fowles, Krista
    Ropchan, Jim
    Emory, Paul
    Ye, Yunpeng
    Nabulsi, Nabeel
    Matuskey, David
    Angarita, Gustavo
    Duman, Ronald
    Sanacora, Gerard
    Krystal, John
    Carson, Richard
    Esterlis, Irina
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S35 - S35
  • [36] Developmental Expression of Synaptic Vesicle Protein SV2A
    Vendrame, Martina
    Talos, Delia
    Chang, Meayoung
    Jensen, Frances
    NEUROLOGY, 2009, 72 (11) : A347 - A347
  • [37] New SV2c construct for use in binding and detecting botulinum neurotoxin type A
    Christian, T.
    Suryadi, K.
    Shine, N.
    TOXICON, 2013, 68 : 84 - 84
  • [38] Structural insights into the interaction of botulinum neurotoxin a with its neuronal receptor SV2C
    Li, Xiaodan
    Brunner, Cyrill
    Wu, Yufan
    Leka, Oneda
    Schneider, Gisbert
    Kammerer, Richard A.
    TOXICON, 2020, 175 : 36 - 43
  • [39] Capture assay for Botulinum Neurotoxin Type A utilizing the receptor protein SV2c
    Christian, Todd
    Shine, Nancy
    TOXICON, 2008, 51 : 2 - 2
  • [40] Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides as Receptors
    Peng, Lisheng
    Tepp, William H.
    Johnson, Eric A.
    Dong, Min
    PLOS PATHOGENS, 2011, 7 (03):